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Abstract
Here we present a web interface that implements a comprehensive mechanistic
model of the SARS-CoV-2 disease map. In this framework, the detailed activity of the
human signaling circuits related to the viral infection, covering from the entry and
replication mechanisms to the downstream consequences as inflammation and
antigenic response, can be inferred from gene expression experiments. Moreover,
the effect of potential interventions, such as knock-downs, or drug effects (currently
the system models the effect of more than 8000 DrugBank drugs) can be studied.
This freely available tool not only provides an unprecedentedly detailed view of the
mechanisms of viral invasion and the consequences in the cell but has also the
potential of becoming an invaluable asset in the search for efficient antiviral
treatments.
Keywords: Mechanistic modeling, Signaling pathway, Drug discovery, COVID-19,
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Introduction
The recent pandemic of COVID-19 (Coronavirus Disease-2019), an emerging respira-
tory disease caused by the SARS-CoV-2 virus, which spread more efficiently than pre-
vious highly pathogenic coronaviruses SARS-CoV and MERS-CoV, has led to a
tremendous toll of affected cases and over 500,000 fatalities in more than 200 countries
since its first outbreak in late 2019 [1]. Precisely due to the rapid transmission of this
novel pathogen, no antiviral drugs or vaccines are available for SARS-CoV-2.
Understanding the molecular mechanisms that mediate SARS-CoV-2 infection is key
for the rapid development of efficient preventive or therapeutic interventions against
the COVID-19. A comprehensive description of such molecular mechanisms is repre-
sented in the corresponding disease map, that is, the sub-module of the whole pathway
of known human protein functional interactions that summarize details of the disease
mechanism and consequently are relevant for understanding the disease [2]. The re-
cent availability of a detailed catalog of viral-human protein interactions [3] has
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facilitated the construction of a first version of a map of the human molecular pathways
involved in the viral infection and downstream consequences [4].
Disease maps are repositories of knowledge of disease-relevant mechanisms that pro-
vide qualitative guidance for the interpretation of experimental findings [2]. Actually,
disease maps are the supporting foundation of different tools able to model the infor-
mation contained in them in order to provide a detailed quantitative explanation for
experimental results [5]. In particular, mechanistic models of disease maps are becom-
ing increasingly relevant for genomic data interpretation because they provide a natural
link between omics data measurements and cell behavior and outcome [6], which ul-
timately accounts for the phenotype of the infection. The knowledge of these links al-
lows a better understanding of the molecular mechanisms of the viral infection and the
responses to drugs. Actually, mechanistic models of human signaling [7] or metabolic
pathways [8] have been successfully used to uncover specific molecular mechanisms be-
hind different cancers [7, 9–11], rare [12] and common [13] diseases, to reveal mecha-
nisms of action of drugs [14], and dissecting them at single cell level [15], to suggest
personalized treatments [16, 17] and in other biologically interesting scenarios [18, 19].
Basically, mechanistic models analyze experimental values in the context of the disease
map information, which is used to point out the relevant aspects of the molecular
mechanisms behind the experiment. It is important to note that this assessment is
made from a systems biology perspective, in the holistic context of the disease map,
and considers the functional interactions among the gene products as described in the
map. Typically, these experimental values are gene expression transcriptomic data, al-
though other data such as proteomic, phosphoproteomic, genomic [20], or even methy-
lomics, can also be used. Interestingly, beyond its usefulness for the functional
interpretation of experimental results, the most remarkable property of mechanistic
models is that they can be used to predict the effects of interventions (inhibitions, over-
activations, drugs, etc., alone or in combinations) over proteins of the map in the
condition studied [21]. Therefore, this opens the possibility of using these models for
exploring new therapeutic options as well [22].
Methods
To construct a first approach to the COVID-19 disease map, the SARS-CoV-2 virus-
human interactome was firstly expanded from existing KEGG pathways [23] to define
regions within the whole set KEGG pathways that potentially account for the molecular
mechanism of the viral infection and the downstream consequences. Pathways are
composed of individual signaling circuits (sub-pathway that describes the chain of sig-
nal transduction that connects a receptor protein to an effector protein) whose func-
tionalities can be described by the UniProt [24] functional annotations of their effector
nodes [7, 25]. It order to restrict the map to those circuits relevant for the COVID-19
disease mechanism, only signaling circuits with at least one UniProt [24] function that
fit in one of these virus-related categories: 1) Host-virus interaction, 2) inflammatory
response, 3) immune activity, 4) antiviral defense, 5) endocytosis were selected to define
the COVID-19 disease map. The model presented here is a part of an ongoing more
detailed repository of SARS-CoV-2 mechanisms, the COVID-19 Disease Map, in con-
struction by an international community, whose most recent version is available at:
https://doi.org/10.17881/covid19-disease-map. In addition to the human version of the
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COVID-19 map, versions for animal models, like mouse or rat, using the homologous
pathways are also provided by the tool [4].
The mechanistic model implemented here takes a directed graph (in this case a first
version of the COVID-19 map, and in the future new versions as these are released),
and extracts from it the collection of signaling circuits that connect receptor nodes to
effector nodes. The signal transduction across such circuits, Sn, is estimated using gene
expression values as proxies of protein activity [26] using the following recursive equa-
tion [7]:
Sn ¼ υn∙ 1 −
Y
sa∈A





1 − sið Þ ð1Þ
Sn is the signal intensity for the current node n, vn is its normalized gene expression
value, A is the set of activation signals (sa), arriving to the current node from activation
edges, Iis the set of inhibitory signals (si) arriving to the node from inhibition edges.
The Sn values of circuits are further used in comparisons to detect increases or de-
creases in signaling activity (and consequently in the corresponding cell functionality),
or to infer the effect of interventions in signaling or the potential resulting phenotype
of mutations.
Implementation
Here, we present the first implementation of a mechanistic model of the SARS-CoV-2
infection in a user-friendly web interface. The model used here implements the
HiPathia [7] algorithm, which has demonstrated to outperform other competing algo-
rithms in a recent benchmarking [25]. The mechanistic model implemented in
HiPathia has been successfully used to understand the disease mechanisms behind dif-
ferent cancers [7] and was able to predict cancer vulnerabilities with a high precision
[9]. The model has been implemented in a user-friendly web application that inputs
normalized gene expression values (or similar proteomics or phosphoproteomic values)
and can be found at http://hipathia.babelomics.org/covid19/. As an example, we carried
out some analyses that involve a case-control differential signaling analysis using a re-
cently published gene expression experiment [27] with human lung cell lines infected
with SARS-CoV-2 (GEO id: GSE147507, the dataset GSE147507_RawReadCounts_
Human.ts). The infected cells showed a differential activation pattern in circuits related
to virus entrance to cell, activation of immune, inflammatory and other virus-triggered
responses (see Fig. 1a and Table 1 for a detailed list of differentially activated signaling
circuits and Table 2 for detail on the differentially activated cell functionalities). Inter-
estingly, several of the deregulated pathways include TNF, a target gene of chloroquine,
one of the drugs with promising results against COVID-19 [28]. Moreover, NF-kB sig-
naling pathway has been highlighted in several studies as one of the main pathways re-
sponsible for COVID-19 progression [29] (Fig. 1 B). Figure 1c depicts the heathmap of
signaling activity profiles that discriminate the two classes of samples (cases and con-
trols) compared. The results found are consistent with those of previous analyses with
the same data, where a modest but generalized response of mechanisms related to im-
mune response and inflammatory processes, such as response to chemokine and
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cytokines, virus defense-related processes, and other general functions of cell like apop-
tosis or cell differentiation was demonstrated [27]. Interestingly, the processes
highlighted by the authors are response to chemokines and interferon-related signaling
pathways. Both processes are highly associated with pathways in whose circuits our
model detect significant deregulations (see Table 1), such as Toll-like and TNF signal-
ing pathways. The relation between chemokines, interferon and Toll-like signaling is
Fig. 1 a Activation pattern of NF-KB pathway in lung cell lines infected with SARS-CoV-2. b Detail of NF-KB
pathway’s circuit with TNF as effector protein. c Heatmap representing activation values of all the circuits in
COVID-19 disease map (left) and a representation of a Principal Component Analysis based on signaling
profiles of the samples that clearly segregates the two conditions studied: controls are represented in dark
blue and cases in purple (right). d An example of the Perturbation effect option simulating the effect of
Siltuximab (targeting IL6 protein) in Toll-like signaling pathway. Individual gene expression levels in each
node are represented green scale. e An example of the Variant interpreter option simulating the effect of a
loss of function mutation in NFKBIA protein over lung tissue pathway activity in the TNF signaling pathway.
Mean values of gene expression levels in each node are represented in green scale
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Table 1 Circuits from CoV-Hipathia differentially activated in lung cell lines infected with SARS-CoV-2
KEGG pathway: effector gene/s UP/ DOWN statistic p-valuea FDRb FCc log FC
MAPK signaling pathway: NLK UP 2.882 2.16E-03 0.023 1.098 0.135
MAPK signaling pathway: STK3 UP 2.882 2.16E-03 0.023 1.209 0.274
MAPK signaling pathway: ECSIT, TRAF6 UP 2.882 2.16E-03 0.023 1.182 0.241
Ras signaling pathway: REL UP 2.882 2.16E-03 0.023 1.074 0.103
Ras signaling pathway: MLLT4 UP 2.882 2.16E-03 0.023 1.049 0.069
NF-kappa B signaling pathway: CFLAR UP 2.882 2.16E-03 0.023 1.212 0.278
NF-kappa B signaling pathway: BIRC2 UP 2.882 2.16E-03 0.023 1.261 0.335
NF-kappa B signaling pathway: XIAP UP 2.882 2.16E-03 0.023 1.176 0.234
NF-kappa B signaling pathway: BCL2L1 UP 2.882 2.16E-03 0.023 1.193 0.254
NF-kappa B signaling pathway: GADD45B UP 2.882 2.16E-03 0.023 1.179 0.238
NF-kappa B signaling pathway: BCL2A1 UP 2.882 2.16E-03 0.023 1.570 0.651
NF-kappa B signaling pathway: NFKB2 UP 2.882 2.16E-03 0.023 1.225 0.293
NF-kappa B signaling pathway: CXCL8 UP 2.882 2.16E-03 0.023 1.185 0.245
NF-kappa B signaling pathway: IL1B UP 2.882 2.16E-03 0.023 1.341 0.424
NF-kappa B signaling pathway: TNFAIP3 UP 2.882 2.16E-03 0.023 1.311 0.390
NF-kappa B signaling pathway: NFKBIA UP 2.882 2.16E-03 0.023 1.254 0.327
NF-kappa B signaling pathway: PTGS2 UP 2.882 2.16E-03 0.023 1.267 0.341
NF-kappa B signaling pathway: CXCL2 UP 2.882 2.16E-03 0.023 1.335 0.417
NF-kappa B signaling pathway: IKBKG, CHUK, IKBKB UP 2.882 2.16E-03 0.023 1.110 0.151
NF-kappa B signaling pathway: BCL2L1 UP 2.882 2.16E-03 0.023 1.098 0.135
NF-kappa B signaling pathway: BCL2A1 UP 2.882 2.16E-03 0.023 1.448 0.534
HIF-1 signaling pathway: TIMP1 UP 2.882 2.16E-03 0.023 1.051 0.072
HIF-1 signaling pathway: TIMP1 UP 2.882 2.16E-03 0.023 1.051 0.072
HIF-1 signaling pathway: EDN1 UP 2.882 2.16E-03 0.023 1.121 0.164
HIF-1 signaling pathway: NOS2 UP 2.882 2.16E-03 0.023 1.585 0.664
HIF-1 signaling pathway: PDK1 UP 2.882 2.16E-03 0.023 1.037 0.052
HIF-1 signaling pathway: PGK1 UP 2.882 2.16E-03 0.023 1.048 0.068
HIF-1 signaling pathway: LDHA UP 2.882 2.16E-03 0.023 1.047 0.066
mTOR signaling pathway: VEGFA UP 2.882 2.16E-03 0.023 1.059 0.083
mTOR signaling pathway: TSC1 DOWN −2.882 2.16E-03 0.023 0.946 −0.080
PI3K-Akt signaling pathway: BCL2L11 DOWN −2.882 2.16E-03 0.023 0.918 −0.123
Apoptosis: FADD, TRADD UP 2.882 2.16E-03 0.023 1.118 0.161
Apoptosis: IRAK3, MYD88 UP 2.882 2.16E-03 0.023 1.167 0.223
Toll-like receptor signaling pathway: CXCL10 UP 2.882 2.16E-03 0.023 1.518 0.602
Toll-like receptor signaling pathway: IFNA1 UP 2.882 2.16E-03 0.023 1.486 0.572
Toll-like receptor signaling pathway: IL1B UP 2.882 2.16E-03 0.023 1.172 0.229
Toll-like receptor signaling pathway: IL6 UP 2.882 2.16E-03 0.023 1.526 0.610
RIG-I-like receptor signaling pathway: MAPK14 UP 2.882 2.16E-03 0.023 1.214 0.280
RIG-I-like receptor signaling pathway: MAVS, TMEM173 UP 2.882 2.16E-03 0.023 1.204 0.268
RIG-I-like receptor signaling pathway: IRF7 UP 2.882 2.16E-03 0.023 1.540 0.623
Ras signaling pathway: MAPK8 UP 2.722 4.33E-03 0.035 1.043 0.061
NF-kappa B signaling pathway: TRAF1 UP 2.722 4.33E-03 0.035 1.193 0.254
NF-kappa B signaling pathway: TNF UP 2.722 4.33E-03 0.035 1.639 0.713
HIF-1 signaling pathway: TFRC UP 2.722 4.33E-03 0.035 1.049 0.068
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well-known [30, 31], moreover, interferon is a key player in TNF signaling pathway
[32], and both signaling pathways are interrelated. Beyong the pure interpretation of
the results, another novel and very useful option of the implementation of the model is
the Perturbation effect. It allows estimating the effect of interventions (inhibitions or
overexpression) across the signaling circuits of the model in a given condition. More-
over, the effect of more than 8000 targeted drugs from DrugBank can be predicted by
selecting them, individually or in combinations. Figure 1d shows and example of the
Perturbation effect option in which the impact of Siltuximab, a drug in study in patients
with COVID-19 respiratory failure [33] which targets protein IL6, is simulated. Individ-
ual gene expression levels in each node are represented in shades of grayish green.
Figure 1e, shows an example of the Variant interpreter option simulating the effect of a
Table 1 Circuits from CoV-Hipathia differentially activated in lung cell lines infected with SARS-CoV-2
(Continued)
KEGG pathway: effector gene/s UP/ DOWN statistic p-valuea FDRb FCc log FC
Sphingolipid signaling pathway: SMPD2 UP 2.722 4.33E-03 0.035 1.388 0.473
Apoptosis: FADD, TRADD UP 2.722 4.33E-03 0.035 1.358 0.442
Apoptosis: TRAF2, RIPK1, TRADD UP 2.722 4.33E-03 0.035 1.358 0.442
Toll-like receptor signaling pathway: TNF UP 2.722 4.33E-03 0.035 1.434 0.520
TNF signaling pathway: CASP7 UP 2.722 4.33E-03 0.035 1.388 0.473
TNF signaling pathway: CASP3 UP 2.722 4.33E-03 0.035 1.371 0.455
TNF signaling pathway: BAG4 UP 2.722 4.33E-03 0.035 1.391 0.476
a P-value is calculated using Wilcoxon test
b FDR refers to p-value adjusted for multiple comparisons using Benjamini and Hochberg method
c FC means Fold Change
Table 2 Functions from CoV-Hipathia differentially activated in lung cell lines infected with SARS-CoV-2
UniProt function UP/DOWN statistic p-valuea FDRb FCc logFC
Innate immunity UP 2.882 2.16E-03 0.018 1.048 0.067
Immunity UP 2.882 2.16E-03 0.018 1.019 0.028
Inflammatory response UP 2.882 2.16E-03 0.018 1.028 0.041
Antiviral defense UP 2.882 2.16E-03 0.018 1.192 0.253
Pyrogen UP 2.882 2.16E-03 0.018 1.177 0.235
Prostaglandin biosynthesis UP 2.882 2.16E-03 0.018 1.267 0.341
Prostaglandin metabolism UP 2.882 2.16E-03 0.018 1.267 0.341
Fatty acid biosynthesis UP 2.882 2.16E-03 0.018 1.266 0.341
Lipid biosynthesis UP 2.882 2.16E-03 0.018 1.266 0.341
Acute phase UP 2.882 2.16E-03 0.018 1.526 0.610
Osteogenesis UP 2.882 2.16E-03 0.018 1.181 0.241
Autophagy DOWN −2.722 4.33E-03 0.028 0.976 −0.035
Translation regulation UP 2.722 4.33E-03 0.028 1.015 0.022
Sphingolipid metabolism UP 2.722 4.33E-03 0.028 1.388 0.473
Necrosis UP 2.562 8.66E-03 0.046 1.009 0.013
Fibrinolysis UP 2.562 8.66E-03 0.046 1.103 0.141
Plasminogen activation UP 2.562 8.66E-03 0.046 1.072 0.101
a P-value is calculated using Wilcoxon test
b FDR refers to p-value adjusted for multiple comparisons using Benjamini and Hochberg method
c FC means Fold Change
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loss of function mutation in NFKBIA gene product over lung tissue pathway activity.
One of the affected circuits in TNF signaling pathway is shown. Mean values of gene
expression levels in each node are represented in shades of grayish green. A detailed
description of the usage of the tool can be found in the accompanying help and
tutorial.
Despite the limitations due to the few samples available, the results of the example
clearly show the usefulness of this tool for modelling the repertoire of cell responses
triggered by SARS-CoV-2, and the enormous potential that it has for future COVID-19
research and discovery of therapeutic interventions. Moreover, in spite of its short life
CoV-Hipathia has already been quoted among other useful web tools to fight the
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